Description: Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company offers blood-based tests across the lung cancer continuum of care, such as Nodify XL2 and Nodify CDT tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules; and GeneStrat tumor profiling and VeriStrat immune profiling tests provide physicians with timely results to facilitate treatment decisions. It also offers include diagnostic research, clinical research, development, and testing services to biopharmaceutical companies, as well as develops and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated 2005 and is headquartered in Boulder, Colorado.
Home Page: www.biodesix.com
BDSX Technical Analysis
2970 Wilderness Place
Boulder,
CO
80301
United States
Phone:
303 417 0500
Officers
| Name | Title |
|---|---|
| Mr. Scott Hutton | Pres, CEO & Director |
| Ms. Robin Harper Cowie | CFO, Sec. & Treasurer |
| Mr. Ryan H. Siurek | Chief Accounting Officer |
| Dr. Heinrich Röder | Founder & CTO |
| Dr. Robert W. Georgantas III, Ph.D. | Chief Scientific Officer |
| Mr. Jeffrey A. Bojar | VP of Legal and Regulatory Affairs |
| Mr. Matt Stauffer | VP of Sales |
| Dr. Paul J. Beresford | Chief Bus. Officer |
| Dr. Gary Anthony Pestano Ph.D. | Chief Devel. Officer |
| Ms. Bobbi Coffin | Chief Growth Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.6374 |
| Price-to-Sales TTM: | 3.6082 |
| IPO Date: | 2020-10-28 |
| Fiscal Year End: | December |
| Full Time Employees: | 218 |